Follow up to results

10-MAR-17

Some more on the Aspen H1 results from yesterday. Make sure that you watch this fabulous interview (that lasted longer than initially) - Aspen H1 normalised HEPS up 6%, see the imbedded video below. Self inflicted (supply chain) problems in South Africa, those have been fixed and a turnaround is afoot. An interesting question, when asked about why own Aspen today, at these levels, he gives an answer which I suspect a shareholder should expect. He said that 40 reporting periods of increased earnings, time and time again, tells you something. And he tells of how the business was harder at the beginning, cap in hand sitting in front of the bank manager. In some ways he says, it is easier to run a bigger business. Interesting perspective, not too dissimilar to those of Phil Knight of Nike in his book, Shoe Dog.


Read more...

Aspen HY 2017 - locking down purchases

09-MAR-17

Aspen released numbers for their six months to end December this morning. This is a business that has transformed from being a small to major generics business, to now positioning themselves as a (in their words) "global, multinational organisation focused on therapeutic specialties." Anticoagulants (to treat thrombosis) and anesthetics, much of this is new business. This compliments their older businesses, infant nutritional (formula and the like) and lastly the High Potency & Cytotoxics division.


Read more...

Aspen's fine in Italy

20-OCT-16

I read (thanks to Google alerts) that Aspen to appeal Italian Competition Authority fine for alleged excessive price hikes. When is it acceptable to stick up the price of a therapy? Aspen are arguing, as per the news article, that they were charging 2 Euros (30.41 Rand) per pill. A pill a day for a month is then 912 Rand, 60 Euros of course. These are blood cancer drugs and were approved for sale back in 2013.


Read more...

GSK sells all their Aspen

03-OCT-16

It was bound to happen sooner or later, the news filtered through Wednesday evening via Reuters that GlaxoSmithKline (GSK) were selling their remaining stake in Aspen. Stephen Saad was asked at the CNBC Africa's awards ceremony on Thursday evening what he thought of all of this, and about the future of the business. 28.2 million shares, or 6.2 percent of the business was placed via an accelerated bookbuild. No price was given. Back to the interview, Saad was given the "All Africa Business Leaders Award for Southern Africa" - here is the interview: Aspen CEO wins the AABLA 2016 Entrepreneur of the Year award.


Read more...

Aspen FY 2016 numbers

15-SEP-16

Aspen results! Those were released mid afternoon here in Jozi, the stock reacted positively, notwithstanding being smashed last week when the trading statement revealed the BS they have to put up with in Venezuela. Stephen Saad said that when the Venezuelan Deputy President was here in Msanzi not so long ago, spewing garbage about their awesomeness (how can you tell I am not a fan?), there were assurances of being paid, and guess what? They didn't materialise! What a twist, socialists lying!!! In theory sharing is actually caring, when big purple dinosaurs tell you to do so with biscuits or crisps or plastic play things, when we grow up instinct kicks in. I am afraid whilst we can organise ourselves into some sort of working patterns in cities and in the workplace (and so on), the early instincts of oneupmanship still remain, it is hard coded to perform better than your peers. You can try and take that away, sorry, it doesn't work.


Read more...

Aspen update on GSK deal

13-SEP-16

Aspen released an update that had several parts to it. This is all ahead of their results which are tomorrow, with the presentation of said results on Thursday, Michael is heading off to the results. I hope he sleeps on Wednesday night and isn't too excited. You can find the release from yesterday here - Aspen GSK Announcement. The first part of the release deals with a transaction in which Aspen Global Incorporated (AGI) will acquire from GlaxoSmithKline (GSK) a series of five established medicines, one general anaesthetic (Ultiva) and then four muscle relaxants (Nimbex, Mivacron, Tracrium and Anectine). According to the Ultiva website, the drug is rapid response and has an equally rapid recovery. Used for spine, orthopaedic, Ear Nose and Throat (ENT), cardiac and other procedures. Wikipedia suggests that the active ingredient in Ultiva, Remifentanil, is 100 to 200 times as potent as morphine. Whoa!


Read more...

Aspen negative trading update

08-SEP-16

Another stock that is taking heat this morning is Aspen Pharmacare. They released a trading statement yesterday afternoon late, after market closed. The company is taking a 870 million Rand hit on the Venezuelan Bolivar having devalued so much. That country is broken. The bus driver president, hand picked by Hugo Chavez, has inherited dumb economic policies that have driven the country off a cliff. Herewith the table that lays out the comparable and what they are likely to be:


Read more...

Aspen debt raise & deal with AstraZeneca

09-JUN-16

Two sets of news from Aspen yesterday and then this morning. First, the news came yesterday afternoon that the company had obtained funding facilities of 3 billion Euros. I will do a copy and paste of the announcement:


Read more...

Aspen 6 month numbers - still showing good growth

04-MAR-16

Aspen Pharma released numbers yesterday afternoon, remembering that we covered their trading update a while ago -> Aspen Trading statement. That was pretty detailed, for a trading update. I guess the reason why we went into all the detail was simple, the stock has really performed badly. And often people refer to the company and the stock price as one and the same, we are all guilty of that. So, I guess when the share price is sliding away, there is something "wrong" with the company, when the stock price goes up, it has to be a "good one". Human nature dictates this to be so, for many of us.


Read more...

Aspen Trading statement

24-FEB-16

Finally. And by that I mean the share price of Aspen Pharma moving northwards in a serious manner. Year to date the stock is still down 6.62 percent, the move yesterday was up nearly nine and a half percent. The stock is up over 21 percent in less than two weeks. As we pointed out, the stock is still down year to date and over the last 12 months the stock is down over 31 percent. 5 years? Up 246 percent. As ever with stocks, it depends where you draw your line in the sand when measuring performance. Why has the stock moved so much in the last little while? Yesterday the company released a trading update, we can do a copy and paste of the table from the SENS announcement:


Read more...

Aspen full year numbers

10-SEP-15

Aspen released results for their full year to end June 2015. This is a company that operates in 70 countries across the world and distributes their products across 150 countries. Wow. They have divested 800 million Dollars in a number of transactions, equally they have done three large transactions in the same year, not ideal to do them all in the same year said the CEO Stephen Saad. Revenue grew 22 percent to 36.1 billion Rand, operating profits increased by 14 percent to 8.4 billion Rand. Of that, South Africa is now around one quarter of revenue (23 percent to be exact, 21 percent of profits), as Stephen Saad says, it will always be their home. See segmented revenues below per region:


Read more...

The reason for Aspen selling part of their Aus opperations

26-MAY-15

Why did Aspen seemingly sell a sizeable portion of their Australian business? It took me a little while to figure it out, first and foremost the Price Disclosure Reductions for 2015 April Cycle from the Australian government Department of Health might reveal that margins for manufacturers Down Under are going to become harder to maintain. If the government, anywhere in the world, wants to get your business to sell your manufactured goods at a lower and lower rate (and not let the market decide ultimately) then I guess it may be a good idea to sell that business. I think if the Australian government covers all and sundry for their healthcare needs, then I guess they can set or stipulate the prices, all I know in the long run, setting prices promotes less and less competition. If you do it in an orderly manner, then I suspect you still attract business.


Read more...

Aspen sells a few more non-core assets

21-MAY-15

Aspen is selling more non-core assets, this time to Stride Entities in Australia: Divestment Of Portfolio Of Branded And Generic Products To Strides Entities. They are doing two transactions the first is a deal to sell 130 products for A$265 million, which contributed A$26 million in pre-tax profit. The second is the selling of 6 branded products for $92 million, which contributed $10 million in pre-tax profits. Given that these are non-core assets and they are being sold for what would appear good prices, I think it is a good move. These funds can be used to pay down debt or used to purchase other assets that Aspen feel they can get better growth and value out of. Remember that they are still trading under a cautionary because there is a possible baby formula deal in the pipe line, which could be huge and require the funds that they are freeing up. The management team have proved that they are solid and shrewd deal makers, we back them to know where the best returns can be made for shareholders.


Read more...

Aspen cautionary - buying an new asset

15-MAY-15

Aspen out with a very short announcement post market yesterday: "Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business." Seeing as the business is global in nature these days (see, currency volatility!), the company could be making this acquisition almost anywhere. Any guesses, Brazil perhaps? Or perhaps somewhere in Eastern Europe? South East Asia? And perhaps the existing business of one of the majors.


Read more...

Aspen sells part of a division

13-MAY-15

What happened with Aspen and Litha? You may have seen in the news that there was a deal of some sort, for 1.6 billion Rand. This was Aspen selling their injectables and established brands business unit to Endo, who own Litha. It looks like a decent price, this business that Apsen are selling for that 1.6 billion Rand price had revenues of 362 million Rand and pre-tax profits of 136 million Rand, as of June 30, 2014. At the same stage, group revenue was 29.5 billion Rand. As you can see, this was a little over one percent of group revenue, and an even smaller part of profits.


Read more...

Older stories...

Watch HotStocks on CNBC Africa, DStv channel 410 8pm and 8am

Newsletter Sign Up

Sign up for our free daily market newsletter.

Paul Theron's Tweets

Sasha Naryshkine's Tweets

Byron Lotter's Tweets

Michael Treherne's Tweets

Bright Khumalo's Tweets